Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD At the recent American Society of Hematology (ASH) Annual Meeting, Kelsey Natsuhara, MD, a Fellow in Hematology and Oncology at the University of California, San Francisco, sat down with Oncology Data Advisor and ConveyMED to discuss...
Multiple Myeloma Trials and Quality News Reporting With Manni Mohyuddin, MBBS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · ASH 2022 Conversations on Multiple Myeloma (Part 1) With Manni Mohyuddin, MBBS At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Manni Mohyuddin, Assistant Professor at the University of Utah Huntsman Cancer Institute, sat down with Oncology Data Advisor to discuss the multiple myeloma research he was involved with at this year's meeting. Dr. Mohyuddin elaborates on his abstracts regarding the prognostic value of (11;14) translocation in multiple myeloma, the characterization of survival end points in clinical trials, and ways to improve the quality of news reporting of oncology clinical trials.  
Additional Advances in Acute Leukemia Research and Clinical Trials: Amir Fathi, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Additional Advances in Acute Leukemia Research and Clinical Trials: Amir Fathi, MD In January 2022, Dr. Amir Fathi, Associate Professor of Medicine at Harvard Medical School and Program Director of the Center for Leukemia at Massachusetts General Hospital, served as faculty for Therapy of Acute B-Cell Leukemia: An Evolving Treatment Landscape, a session presented during the ODACon Rare Hematologic Malignancies Symposium. Recently, numerous significant updates in both ALL and acute myeloid leukemia (AML) were presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans. In this interview, Dr. Fathi elaborates on these exciting developments in the ever-changing treatment landscape for acute leukemia.
Additional Advances in Squamous Non–Small Cell Lung Cancer Research and Clinical Trials With Mark Kris, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Additional Advances in Squamous NSCLC Research and Clinical Trials With Mark Kris, MD In 2022, Dr. Mark Kris, the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, served as chair of Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer (NSCLC), a continuing medical education (CME)/nursing continuing professional development (NCPD) activity. A year later, Dr. Kris sat down again with Oncology Data Advisor to share the progress that has occurred in this field and the important considerations to keep in mind when treating patients with squamous NSCLC in 2023.
Pioneering the Field of Stem Cell Biology With Irving Weissman, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Pioneering the Field of Stem Cell Biology With Irving Weissman, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.  
Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MD Currently, Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center, is the chair of Optimizing Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma, a continuing medical education/nursing continuing professional development (CME/NCPD)–accredited live or virtual meeting series provided by i3 Health. In this interview, Dr. Kumar provides a glimpse into the exciting developments in multiple myeloma research that are covered in the program, including breaking updates from the 2022 American Society of Hematology (ASH) Annual Meeting.
Additional Advances in Multiple Myeloma Research and Clinical Trials: With Sarah Holstein, MD, PhD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Additional Advancements in Research: Multiple Myeloma Click here to view and claim credit for Expert Perspectives on Practice-Changing Strategies and Improved Patient Outcomes in Multiple Myeloma, an accredited CME activity provided by i3 Health.Part 1: https://i3health.com/management-of-mm-pt1Part 2: https://i...
CLL Society: A Valuable Resource for Patients and the Health Care Team, With Founder Brian Koffman, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · CLL Society, a Valuable Resource for Patients and the Health Care Team: Brian Koffman, MD In this interview, Oncology Data Advisor speaks with Dr. Brian Koffman, founder of CLL Society, a nonprofit organization focused on patient education, support, and research for chronic lymphocytic leukemia (CLL). Dr. Koffman shares his personal story and how it led him to establish CLL Society and explains how the valuable resources they provide can benefit both patients with CLL and the health care team members who treat and support them. 
Personalizing Prostate Cancer Therapy With Christopher Iannuzzi, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Personalizing Prostate Cancer Therapy With Christopher Iannuzzi, MD In this interview, Oncology Data Advisor speaks with Dr. Christopher Iannuzzi of Hartford HealthCare about an ongoing clinical trial investigating the personalization of prostate cancer treatment through genomic tumor testing. In addition, Dr. Iannuzzi shares the advantages of delivering stereotactic body radiation therapy and the importance of undergoing prostate cancer screening.  
Additional Advances in Waldenstrom Macroglobulinemia Research and Clinical Trials With Morie Gertz, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Recent Updates in Waldenstrom Macroglobulinemia With Morie Gertz, MD In January 2022, Dr. Morie Gertz, Professor and Chair of General Internal Medicine at the Mayo Clinic in Minnesota, served as faculty for the Waldenstrom macroglobulinemia session of the Oncology Data AdvisorTM Hematologic Malignancies Symposium. With several significant updates in the treatment and management of WM since then, Dr. Gertz sat down with Oncology Data Advisor again to share all that has occurred in this evolving field.
Understanding Clonal Hematopoiesis in Hematologic Malignancies With Rahul Banerjee, MD, Jeremy Meier, MD, and Samuel Rubinstein, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Understanding Clonal Hematopoiesis With Rahul Banerjee, Jeremy Meier, and Samuel Rubinstein Dr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies. 
Raising Awareness for Breast Cancer Risks in Transgender Patients With Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Raising Awareness for Breast Cancer Risks in Transgender Patients With Valerie Brutus, MD, FACS In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor about the risks for breast cancer in transgender individuals. Dr. Brutus shares the importance of starting the conversation about individualized risk assessment to provide the most appropriate screening recommendations and personalized care for every patient.  
Bringing Attention to Breast Cancer Reconstructive Surgery Options With Elizabeth Stirling Craig, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Bringing Attention to Breast Cancer Reconstructive Surgery Options With Elizabeth Stirling Craig, MD In this latest Breast Cancer Awareness Month interview, Dr. Elizabeth Stirling Craig, Director of Microvascular Breast Reconstruction at St. Vincent's Medical Center of Hartford HealthCare, explains the microsurgical techniques that she performs as a breast reconstructive surgeon and shares the importance of providing patients with a clear picture of the reconstructive options that are available to them. 
Blood Cancer Awareness Month: Exploring Patient-Reported Outcomes With Rahul Banerjee, MD, FACP, and Ajay Major, MD, MBA
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Blood Cancer Awareness Month: Exploring Patient-Reported Outcomes: Rahul Banerjee and Ajay Major Recently, Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Editorial Board member for Oncology Data Advisor, spoke with Dr. Ajay Major, Assistant Professor at the University of Colorado, i...
Personalizing Lung Cancer Care Through Biomarkers and Precision Medicine With Blanca Ledezma, MSN, NP
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Personalizing Lung Cancer Care Through Biomarkers and Precision Medicine: Blanca Ledezma, MSN, NP In this interview with Oncology Data Advisor, Blanca Ledezma, MSN, NP, elucidates the current landscape of therapeutically actionable biomarkers in lung cancer and the promising future of precision medicine in this field. In addition, she explains the clinical applications for lung cancer biomarkers in nursing practice, including unique toxicity management and patient education for novel therapies.  
Caring for Patients Receiving CAR T-Cell Therapy With Joshua Sasine, MD, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Caring for Patients Receiving CAR T-Cell Therapy In this interview with Oncology Data Advisor, Dr. Joshua Sasine, Hematologist-Oncologist at Cedars-Sinai Medical Center, discusses the factors that make patients suitable candidates for chimeric antigen receptor (CAR) T-cell therapy, strategies to minimize the unique toxicities associated with these treatments, and the future of the use of CAR T-cell therapy in the outpatient setting.  
Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS In this interview with Oncology Data Advisor, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center, discusses the significance of Magtrace™, a liquid tracer which has recently become a game changer in guiding surgical decisions for patients with breast cancer.  
World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.  
Tackling Violence and Stigmatization to Decrease Cancer Disparities for Transgender Patients With Ash Alpert, MD, MFA
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Tackling Violence and Stigmatization to Decrease Disparities for Transgender Patients: Ash Alpert At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Dr. Ash Alpert, a postdoctoral fellow in health services research at Brown University, presented two posters regarding the associations between violence and cancer risk factors for transgender and cisgender people. In this follow-up interview with Oncology Data Advisor, Dr. Alpert delves further into the implications of these two studies' results and shares how their ongoing research in this field seeks to improve the care of transgender people in the health care setting.  
Understanding Antibody-Drug Conjugates and Their Use in the Treatment of Breast Cancer With Ian Krop, MD, PhD
Elizabeth Heller, PhD
Expert Analysis
Oncology Data Advisor™ · Patritumab Deruxtecan for HER3-Expressing Metastatic Breast Cancer: Ian Krop, MD, PhD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Ian Krop, Director of the Yale Cancer Center Clinical Trials Office, sat down with Oncology Data Advisor to discuss his research and the data he presented regarding the HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) for treatment of metastatic breast cancer.This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMED.  

Copyright © 2022 Oncology Data Advisor. All rights reserved.